Core Viewpoint - The company acknowledges limitations in its current quality standards, testing methods, and labeling for recombinant collagen products, and has announced three standardization upgrade measures to address these issues [2]. Group 1: Company Response - The company has conducted a comprehensive self-inspection of its recombinant collagen raw materials and products, revealing that existing quality standards and testing methods are increasingly inadequate to meet high industry standards and technological advancements [2][3]. - The company commits to three specific actions: collaborating with research institutions to optimize verification methods, proactively disclosing raw material and finished product data, and participating in the formulation of national standards [2]. Group 2: Background of the Controversy - The controversy regarding recombinant collagen content originated from a May 24 article by "Dr. Big Mouth," which claimed that the collagen content in the company's product "胶原棒1.0" was only 0.0177%, significantly below the labeled threshold of 0.1% [3]. - In response, the company cited industry standard YY/T 1947-2025, asserting that its products contain "greater than 0.1%" collagen, and criticized the testing method used by the opposing party as unverified and unreliable [3]. - The company's flagship product, the "recombinant collagen essence," generated revenue of 4.54 billion yuan in 2024, accounting for 82% of the group's total income [3].
巨子生物发声承认局限性